Qing Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qing Yang has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Shuhong Yi
Department of Hepatic Surgery and Liver Transplantation Center, The Third Affiliated Hospital of Sun Yat-sen University
3 shared publications - Yang Yang
Department of Hepatic Surgery and Liver Transplantation Center of the Third Affiliated Hospital of Sun Yat-sen University; Organ Transplantation Research Center of Guangdong Province, Guangdong Province Engineering Laboratory for Transplantation Medicine, Guangzhou, China
3 shared publications - Binsheng Fu
Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, 600# Tianhe Road, Guangzhou, 510630, China.
2 shared publications - Wei Liu
Department of Hepatic Surgery and Liver Transplantation Center, Organ Transplantation Institute, Organ Transplantation Research Center of Guangdong Province, Guangdong Province Engineering Laboratory for Transplantation Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, China
2 shared publications Wei Meng
Department of Hepatic Surgery and Liver transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University and Organ Transplantation Research Center of Guangdong Province, Guangzhou 510630, China
2 shared publications- Alfred Wei Chieh Kow
Division of Hepatobiliary & Pancreatic Surgery, Department of Surgery, National University of Singapore, Singapore, Singapore
1 shared publication
Latest Publications
- 11 November 2026
- Published by Elsevier in American Journal of Transplantation
CD8 T cell phenotype diagnoses graft-versus-host disease after liver transplantation
- 11 November 2026
- Published by Elsevier in American Journal of Transplantation
CD8 T cell phenotype diagnoses graft-versus-host disease after liver transplantation
- Open Access
- 2 June 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1845162
Normal ALT masks occult liver injury in young chronic hepatitis B patients: a call for early treatment intervention
Background: Guidelines provide limited guidance on antiviral therapy for CHB patients ≤30 years with normal ALT despite occult injury risks. Methods: This multicenter cross-sectional study included 423 treatment-naïve CHB patients aged ≤30 years with persistently normal ALT who underwent liver biopsy. Significant injury was defined as METAVIR necroinflammation ≥G2 and/or fibrosis ≥S2. A non-invasive model was developed and internally validated. Results: Significant necroinflammation and fibrosis were present in 48.0% and 48.5%, respectively. Independent predictors included anti-HBc, LSM, and AST. The Y-HAL model showed excellent discrimination (AUC: 0.918), outperforming 12 existing models. A three-tier pathway stratified patients into low-risk (monitoring), high-risk (antiviral therapy), and intermediate-risk (biopsy) categories. Conclusions: A substantial proportion of young CHB patients with normal ALT have significant histological injury. The Y-HAL model and three-tier strategy offer an evidence-based framework for early intervention.
- 2 June 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1845162
Open AccessNormal ALT masks occult liver injury in young chronic hepatitis B patients: a call for early treatment intervention
Background: Guidelines provide limited guidance on antiviral therapy for CHB patients ≤30 years with normal ALT despite occult injury risks. Methods: This multicenter cross-sectional study included 423 treatment-naïve CHB patients aged ≤30 years with persistently normal ALT who underwent liver biopsy. Significant injury was defined as METAVIR necroinflammation ≥G2 and/or fibrosis ≥S2. A non-invasive model was developed and internally validated. Results: Significant necroinflammation and fibrosis were present in 48.0% and 48.5%, respectively. Independent predictors included anti-HBc, LSM, and AST. The Y-HAL model showed excellent discrimination (AUC: 0.918), outperforming 12 existing models. A three-tier pathway stratified patients into low-risk (monitoring), high-risk (antiviral therapy), and intermediate-risk (biopsy) categories. Conclusions: A substantial proportion of young CHB patients with normal ALT have significant histological injury. The Y-HAL model and three-tier strategy offer an evidence-based framework for early intervention.
- Open Access
- 13 June 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (11) , 1979-1993
Cross-species metabolomic profiling reveals phosphocholine-mediated liver protection from cold and ischemia/reperfusion
- 13 June 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (11) , 1979-1993
Open AccessCross-species metabolomic profiling reveals phosphocholine-mediated liver protection from cold and ischemia/reperfusion
- Open Access
- 1 September 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (17) , 1052
Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer
Background: In locally advanced triple-negative breast cancer (TNBC), patients who did not achieve pathologic complete response (non-pCR) after neoadjuvant chemotherapy develop rapid tumor metastasis. Tumor mutation burden (TMB) is a potential biomarker of cancer therapy, though whether it is applicable to TNBC is still unclear. Methods: A total of 14 non-pCR TNBC patients were enrolled, and tissue samples from radical operation were collected. Of these, 7 cases developed disease progression within 12 months after operation [short disease-free survival (short DFS)], while others showed longer DFS over 1 year (long DFS). Next generation sequencing (NGS) analysis targeting 422 cancer-related genes and in vitro studies were performed. Results: A total of 72 mutations were detected within 14 patients, which ranged from 1 to 8 per patient with a median mutations number of 5. The median number of mutations in the short-DFS group was higher than that in the long-DFS group (6.0 vs. 4.3; P=0.094). Furthermore, 6 gene mutation types were detected, with missense mutations displayed in the majority (36/72, 50.0%). No correlation between mutation type and DFS was found. Among 422 cancer-related genes, alterations in 30 genes were detected. TP53 (12/14, 85.7%) was the most common mutation gene in the entire cohort. RB1 mutations significantly occurred in patients with high Ki-67 scores (P=0.013). Additionally, 4 mutations of PTPN13 (57.1%, 4/7) and 3 of JARID2 (42.9%, 3/7) were only detected in the short-DFS group, while patients with JARID2 mutation had a significantly shorter DFS period (P=0.026). Experiments in vitro confirmed that JARID2 gene was widely expressed in various breast cancer cell lines. Knockdown of JARID2 in MD-MBA-231 cells by small interfering RNA (siRNA) decreased the expression of E-cadherin, and increased the levels of vimentin, MMP7, and MMP9. Conclusions: In non-pCR TNBC, JARID2 mutation and TMB elevated in patients with short-DFS, indicating the potential prognostic biomarkers and therapeutic molecular targets for locally advanced TNBC.
- 1 September 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (17) , 1052
Open AccessTumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer
Background: In locally advanced triple-negative breast cancer (TNBC), patients who did not achieve pathologic complete response (non-pCR) after neoadjuvant chemotherapy develop rapid tumor metastasis. Tumor mutation burden (TMB) is a potential biomarker of cancer therapy, though whether it is applicable to TNBC is still unclear. Methods: A total of 14 non-pCR TNBC patients were enrolled, and tissue samples from radical operation were collected. Of these, 7 cases developed disease progression within 12 months after operation [short disease-free survival (short DFS)], while others showed longer DFS over 1 year (long DFS). Next generation sequencing (NGS) analysis targeting 422 cancer-related genes and in vitro studies were performed. Results: A total of 72 mutations were detected within 14 patients, which ranged from 1 to 8 per patient with a median mutations number of 5. The median number of mutations in the short-DFS group was higher than that in the long-DFS group (6.0 vs. 4.3; P=0.094). Furthermore, 6 gene mutation types were detected, with missense mutations displayed in the majority (36/72, 50.0%). No correlation between mutation type and DFS was found. Among 422 cancer-related genes, alterations in 30 genes were detected. TP53 (12/14, 85.7%) was the most common mutation gene in the entire cohort. RB1 mutations significantly occurred in patients with high Ki-67 scores (P=0.013). Additionally, 4 mutations of PTPN13 (57.1%, 4/7) and 3 of JARID2 (42.9%, 3/7) were only detected in the short-DFS group, while patients with JARID2 mutation had a significantly shorter DFS period (P=0.026). Experiments in vitro confirmed that JARID2 gene was widely expressed in various breast cancer cell lines. Knockdown of JARID2 in MD-MBA-231 cells by small interfering RNA (siRNA) decreased the expression of E-cadherin, and increased the levels of vimentin, MMP7, and MMP9. Conclusions: In non-pCR TNBC, JARID2 mutation and TMB elevated in patients with short-DFS, indicating the potential prognostic biomarkers and therapeutic molecular targets for locally advanced TNBC.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in Bioengineered
- Vol. 11 (1) , 1016-1026
Long intergenic noncoding RNA01134 accelerates hepatocellular carcinoma progression by sponging microRNA-4784 and downregulating structure specific recognition protein 1
Dysregulation of long noncoding RNAs (lncRNAs) has been suggested to foster the carcinogenesis of hepatocellular carcinoma (HCC). To date, the role of long intergenic noncoding RNA01134 (LINC01134) in HCC have never been researched yet. Herein, we found that LINC01134 was highly expressed in HCC tissues in comparison with the matched normal liver tissues and increased LINC01134 expression correlated with shorter overall survival of patients with HCC. Additionally, we demonstrated LINC01134 downregulation significantly suppressed the proliferation ability and colony formation capacity of HCC cells. Furthermore, we revealed that LINC01134 functioned as a competitive endogenous RNA (ceRNA) for miR-4784 to upregulate structure-specific recognition protein 1 (SSRP1) in HCC cells. Meanwhile, miR-4784 inhibitor or restoration of SSRP1 could markedly attenuate the inhibitory effect of LINC01134 downregulation on HCC cells. Taken together, LINC01134 may promote the carcinogenesis of HCC at least partly via the miR-4784/SSRP1 axis. Therefore, LINC01134/miR-4784/SSRP1 axis should be developed as the promising therapeutic target for HCC.
- 1 January 2020
- Published by Taylor & Francis in Bioengineered
- Vol. 11 (1) , 1016-1026
Open AccessLong intergenic noncoding RNA01134 accelerates hepatocellular carcinoma progression by sponging microRNA-4784 and downregulating structure specific recognition protein 1
Dysregulation of long noncoding RNAs (lncRNAs) has been suggested to foster the carcinogenesis of hepatocellular carcinoma (HCC). To date, the role of long intergenic noncoding RNA01134 (LINC01134) in HCC have never been researched yet. Herein, we found that LINC01134 was highly expressed in HCC tissues in comparison with the matched normal liver tissues and increased LINC01134 expression correlated with shorter overall survival of patients with HCC. Additionally, we demonstrated LINC01134 downregulation significantly suppressed the proliferation ability and colony formation capacity of HCC cells. Furthermore, we revealed that LINC01134 functioned as a competitive endogenous RNA (ceRNA) for miR-4784 to upregulate structure-specific recognition protein 1 (SSRP1) in HCC cells. Meanwhile, miR-4784 inhibitor or restoration of SSRP1 could markedly attenuate the inhibitory effect of LINC01134 downregulation on HCC cells. Taken together, LINC01134 may promote the carcinogenesis of HCC at least partly via the miR-4784/SSRP1 axis. Therefore, LINC01134/miR-4784/SSRP1 axis should be developed as the promising therapeutic target for HCC.
- Open Access
- 17 June 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-12
Minichromosome maintenance 3 promotes hepatocellular carcinoma radioresistance by activating the NF-κB pathway
Hepatocellular carcinoma (HCC) is the most common tumors in the worldwide, it develops resistance to radiotherapy during treatment, understanding the regulatory mechanisms of radioresistance generation is the urgent need for HCC therapy. qRT-PCR, western blot and immunohistochemistry were used to examine MCM3 expression. MTT assay, colony formation assay, terminal deoxynucleotidyl transferase nick end labeling assay and In vivo xenograft assay were used to determine the effect of MCM3 on radioresistance. Gene set enrichment analysis, luciferase reporter assay, western blot and qRT-PCR were used to examine the effect of MCM3 on NF-κB pathway. We found DNA replication initiation protein Minichromosome Maintenance 3 (MCM3) was upregulated in HCC tissues and cells, patients with high MCM3 expression had poor outcome, it was an independent prognostic factor for HCC. Cells with high MCM3 expression or MCM3 overexpression increased the radioresistance determined by MTT assay, colony formation assay, TUNEL assay and orthotopic transplantation mouse model, while cells with low MCM3 expression or MCM3 knockdown reduced the radioresistance. Mechanism analysis showed MCM3 activated NF-κB pathway, characterized by increasing the nuclear translocation of p65, the expression of the downstream genes NF-κB pathway and the phosphorylation of IKK-β and IκBα. Inhibition of NF-κB in MCM3 overexpressing cells using small molecular inhibitor reduced the radioresistance, suggesting MCM3 increased radioresistance through activating NF-κB pathway. Moreover, we found MCM3 expression positively correlated with NF-κB pathway in clinic. Our findings revealed that MCM3 promoted radioresistance through activating NF-κB pathway, strengthening the role of MCM subunits in the tumor progression and providing a new target for HCC therapy.
- 17 June 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-12
Open AccessMinichromosome maintenance 3 promotes hepatocellular carcinoma radioresistance by activating the NF-κB pathway
Hepatocellular carcinoma (HCC) is the most common tumors in the worldwide, it develops resistance to radiotherapy during treatment, understanding the regulatory mechanisms of radioresistance generation is the urgent need for HCC therapy. qRT-PCR, western blot and immunohistochemistry were used to examine MCM3 expression. MTT assay, colony formation assay, terminal deoxynucleotidyl transferase nick end labeling assay and In vivo xenograft assay were used to determine the effect of MCM3 on radioresistance. Gene set enrichment analysis, luciferase reporter assay, western blot and qRT-PCR were used to examine the effect of MCM3 on NF-κB pathway. We found DNA replication initiation protein Minichromosome Maintenance 3 (MCM3) was upregulated in HCC tissues and cells, patients with high MCM3 expression had poor outcome, it was an independent prognostic factor for HCC. Cells with high MCM3 expression or MCM3 overexpression increased the radioresistance determined by MTT assay, colony formation assay, TUNEL assay and orthotopic transplantation mouse model, while cells with low MCM3 expression or MCM3 knockdown reduced the radioresistance. Mechanism analysis showed MCM3 activated NF-κB pathway, characterized by increasing the nuclear translocation of p65, the expression of the downstream genes NF-κB pathway and the phosphorylation of IKK-β and IκBα. Inhibition of NF-κB in MCM3 overexpressing cells using small molecular inhibitor reduced the radioresistance, suggesting MCM3 increased radioresistance through activating NF-κB pathway. Moreover, we found MCM3 expression positively correlated with NF-κB pathway in clinic. Our findings revealed that MCM3 promoted radioresistance through activating NF-κB pathway, strengthening the role of MCM subunits in the tumor progression and providing a new target for HCC therapy.
- Open Access
- 14 June 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 1356
Inhibition of Autophagy Prolongs Recipient Survival Through Promoting CD8+ T Cell Apoptosis in a Rat Liver Transplantation Model
In liver transplantation (LT), although various immunosuppressants have been used in clinical practice, acute rejection remains a common complication that significantly shortens recipient survival. In recent years, manipulating immune tolerance has been regarded as one of the promising solutions to rejection. Autophagy, an evolutionarily conserved protein degradation system, has been reported to be involved in immune rejection and may be a target to establish immune tolerance. However, the role of autophagy in acute rejection reaction after LT has not been elucidated. Here, we showed that the autophagy of CD8+ T cells was strongly enhanced in patients with graft rejection and that the autophagy level was positively correlated with the severity of rejection. Similar findings were observed in a rat acute hepatic rejection model. Furthermore, administration of the autophagy inhibitor 3-methyladenine (3-MA) largely decreased the viability and function of CD8+ T cells through inhibiting autophagy, which significantly prolonged graft survival in rats. In addition, inhibiting the autophagy of activated CD8+ T cells in vitro considerably suppressed mitochondria mediated survival and downregulated T cell function. Conclusions: We first showed that the inhibition of autophagy significantly prolongs liver allograft survival by promoting the apoptosis of CD8+ T cells, which may provide a novel strategy for immune tolerance induction.
- 14 June 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 1356
Open AccessInhibition of Autophagy Prolongs Recipient Survival Through Promoting CD8+ T Cell Apoptosis in a Rat Liver Transplantation Model
In liver transplantation (LT), although various immunosuppressants have been used in clinical practice, acute rejection remains a common complication that significantly shortens recipient survival. In recent years, manipulating immune tolerance has been regarded as one of the promising solutions to rejection. Autophagy, an evolutionarily conserved protein degradation system, has been reported to be involved in immune rejection and may be a target to establish immune tolerance. However, the role of autophagy in acute rejection reaction after LT has not been elucidated. Here, we showed that the autophagy of CD8+ T cells was strongly enhanced in patients with graft rejection and that the autophagy level was positively correlated with the severity of rejection. Similar findings were observed in a rat acute hepatic rejection model. Furthermore, administration of the autophagy inhibitor 3-methyladenine (3-MA) largely decreased the viability and function of CD8+ T cells through inhibiting autophagy, which significantly prolonged graft survival in rats. In addition, inhibiting the autophagy of activated CD8+ T cells in vitro considerably suppressed mitochondria mediated survival and downregulated T cell function. Conclusions: We first showed that the inhibition of autophagy significantly prolongs liver allograft survival by promoting the apoptosis of CD8+ T cells, which may provide a novel strategy for immune tolerance induction.
- Open Access
- 15 January 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-9
Knockdown of PHF5A Inhibits Migration and Invasion of HCC Cells via Downregulating NF-κB Signaling
Background. Inflammation is the major risk factor for the progression of hepatocellular carcinoma (HCC), and the nuclear factor-κB (NF-κB) signaling plays the central role in the inflammation process. However, the activated mechanism of NF-κB signaling in HCC is unclear. Methods. The expression of PHF5A is examined by qPCR, western blotting, and immunohistochemistry (IHC) assay. The potential of PHF5A (PHD-finger domain protein 5a) for migration and invasion is examined by wound healing and Transwell assay. Luciferase reporter assay, western blotting, and qPCR were applied to explore the mechanism by which PHF5A is involved in progression of HCC. Results. PHF5A was significantly upregulated in HCC tissues and cells. Downregulation of PHF5A inhibits the migration and invasion of HCC cells. Further study demonstrated that PHF5A is implicated in HCC progression through NF-κB signaling. In addition, blocking the NF-κB signaling can weaken the stimulatory effect of PHF5A on migration and invasion of HCC cells. Conclusion. PHF5A expression is upregulated in HCC tissues, and depletion of PHF5A inhibits the migration and invasion of HCC cells. Further experiments demonstrated that PHF5A is implicated in NF-κB signaling and knockdown of PHF5A downregulates the activity of NF-κB pathway to inhibit the tumor progression. The above results provide the evidence that PHF5A plays an indispensable role in progressive effect of NF-κB pathway in HCC and may be a novel therapeutic target of HCC.
- 15 January 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-9
Open AccessKnockdown of PHF5A Inhibits Migration and Invasion of HCC Cells via Downregulating NF-κB Signaling
Background. Inflammation is the major risk factor for the progression of hepatocellular carcinoma (HCC), and the nuclear factor-κB (NF-κB) signaling plays the central role in the inflammation process. However, the activated mechanism of NF-κB signaling in HCC is unclear. Methods. The expression of PHF5A is examined by qPCR, western blotting, and immunohistochemistry (IHC) assay. The potential of PHF5A (PHD-finger domain protein 5a) for migration and invasion is examined by wound healing and Transwell assay. Luciferase reporter assay, western blotting, and qPCR were applied to explore the mechanism by which PHF5A is involved in progression of HCC. Results. PHF5A was significantly upregulated in HCC tissues and cells. Downregulation of PHF5A inhibits the migration and invasion of HCC cells. Further study demonstrated that PHF5A is implicated in HCC progression through NF-κB signaling. In addition, blocking the NF-κB signaling can weaken the stimulatory effect of PHF5A on migration and invasion of HCC cells. Conclusion. PHF5A expression is upregulated in HCC tissues, and depletion of PHF5A inhibits the migration and invasion of HCC cells. Further experiments demonstrated that PHF5A is implicated in NF-κB signaling and knockdown of PHF5A downregulates the activity of NF-κB pathway to inhibit the tumor progression. The above results provide the evidence that PHF5A plays an indispensable role in progressive effect of NF-κB pathway in HCC and may be a novel therapeutic target of HCC.
- Open Access
- 1 April 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 1929-1939
Downregulation of miR-542-3p promotes cancer metastasis through activating TGF-β/Smad signaling in hepatocellular carcinoma
Introduction: Hepatocellular carcinoma (HCC) accounts for more than 90% of primary liver cancer. Although great progress has been made on HCC molecular mechanism and therapy techniques, the prognosis of HCC patient is poor due to high metastasis and recurrence. Materials and methods: Expression of miR-542-3p was quantified by quantitative real-time PCR (qRT-PCR). The role of miR-542-3p in HCC metastasis was examined using transwell and 3D-culture assay. qRT-PCR, Western blotting and luciferase reporter assay were used to elucidate the mechanisms of miR-542-3p-mediated cancer metastasis. Results and Conclusion: In the research, we found that miR-542-3p is decreased in HCC cell lines and tissues, and downregulation of miR-542-3p enhances, while upregulation suppresses HCC cell invasion ability. Further assay demonstrated that miR-542-3p can directly target TGF-β1 3' untranslated region (3'UTR) to influence TGF-β/Smad signaling pathway, and suppression of miR-542-3p can hyperactivate TGF-β/Smad pathway and further to promote Epithelial-Mesenchyme Transition (EMT) and induce poor prognosis. Lastly, the clinical correlation analysis illustrated that miR-542-3p is negatively related with the activity of TGF-β1. In summary, our results find that miR-542-3p takes an important role on HCC progression and provide more evidence of microRNAs (miRNAs) for cancer therapy.
- 1 April 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 1929-1939
Open AccessDownregulation of miR-542-3p promotes cancer metastasis through activating TGF-β/Smad signaling in hepatocellular carcinoma
Introduction: Hepatocellular carcinoma (HCC) accounts for more than 90% of primary liver cancer. Although great progress has been made on HCC molecular mechanism and therapy techniques, the prognosis of HCC patient is poor due to high metastasis and recurrence. Materials and methods: Expression of miR-542-3p was quantified by quantitative real-time PCR (qRT-PCR). The role of miR-542-3p in HCC metastasis was examined using transwell and 3D-culture assay. qRT-PCR, Western blotting and luciferase reporter assay were used to elucidate the mechanisms of miR-542-3p-mediated cancer metastasis. Results and Conclusion: In the research, we found that miR-542-3p is decreased in HCC cell lines and tissues, and downregulation of miR-542-3p enhances, while upregulation suppresses HCC cell invasion ability. Further assay demonstrated that miR-542-3p can directly target TGF-β1 3' untranslated region (3'UTR) to influence TGF-β/Smad signaling pathway, and suppression of miR-542-3p can hyperactivate TGF-β/Smad pathway and further to promote Epithelial-Mesenchyme Transition (EMT) and induce poor prognosis. Lastly, the clinical correlation analysis illustrated that miR-542-3p is negatively related with the activity of TGF-β1. In summary, our results find that miR-542-3p takes an important role on HCC progression and provide more evidence of microRNAs (miRNAs) for cancer therapy.
- 12 January 2017
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 17 (2) , 221-229
Autophagy Inhibits Apoptosis Induced by agrocybe aegerita Lectin in Hepatocellular Carcinoma
Background: Lectins are carbohydrate-binding proteins that exhibit remarkable antitumor activities by inducing apoptotic or autophagic cell death. However, the relationship between apoptosis and autophagy induced by lectins has rarely been reported. Agrocybe aegerita lectin (AAL), a lectin isolated from the fungus Agrocybe aegerita, exerts antitumor activity through apoptosis. Objective: To study the relationship between the autophagy and apoptosis induced by AAL in hepatocellular carcinoma (HCC) cells, and then to promote the antitumor effect of AAL. Method: AAL was evaluateted using the CCK-8 kit and the trypan blue assay. Cell autophagy was studied using western blotting, acridine orange straining, transmission electron microscopy, and transient transfection of pEGFPLC3 plasmids. We also evaluated AAL-induced autophagy in Caenorhabditis elegans. Apoptosis was studied using flow cytometry. We also identified the antitumor effects of co-treatment of AAL with chloroquine (CQ) in vitro and in vivo. Results: AAL-treated cell lines showed accumulation of microtubule-associated protein light chain 3 II (LC3-II), formation of EGFP-LC3 puncta and acidic autophagic vacuoles (AVOs), and the induction of autophagosomes. Inhibition of autophagy could enhance apoptosis induced by AAL in HCC cells. Furthermore, co-therapy (AAL and chloroquine) promote antitumor effect of AAL in a murine in situ HCC model. Conclusion: Our findings suggest that inhibition of autophagy exerts a synergistic effect on the antitumor activity of AAL and may be a helpful strategy for reducing the dosage of lectin used in antitumor therapy. The autophagy inhibitor may be a synergist of certain antitumor drugs that can induce both apoptosis and autophagy.
- 12 January 2017
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 17 (2) , 221-229
Autophagy Inhibits Apoptosis Induced by agrocybe aegerita Lectin in Hepatocellular Carcinoma
Background: Lectins are carbohydrate-binding proteins that exhibit remarkable antitumor activities by inducing apoptotic or autophagic cell death. However, the relationship between apoptosis and autophagy induced by lectins has rarely been reported. Agrocybe aegerita lectin (AAL), a lectin isolated from the fungus Agrocybe aegerita, exerts antitumor activity through apoptosis. Objective: To study the relationship between the autophagy and apoptosis induced by AAL in hepatocellular carcinoma (HCC) cells, and then to promote the antitumor effect of AAL. Method: AAL was evaluateted using the CCK-8 kit and the trypan blue assay. Cell autophagy was studied using western blotting, acridine orange straining, transmission electron microscopy, and transient transfection of pEGFPLC3 plasmids. We also evaluated AAL-induced autophagy in Caenorhabditis elegans. Apoptosis was studied using flow cytometry. We also identified the antitumor effects of co-treatment of AAL with chloroquine (CQ) in vitro and in vivo. Results: AAL-treated cell lines showed accumulation of microtubule-associated protein light chain 3 II (LC3-II), formation of EGFP-LC3 puncta and acidic autophagic vacuoles (AVOs), and the induction of autophagosomes. Inhibition of autophagy could enhance apoptosis induced by AAL in HCC cells. Furthermore, co-therapy (AAL and chloroquine) promote antitumor effect of AAL in a murine in situ HCC model. Conclusion: Our findings suggest that inhibition of autophagy exerts a synergistic effect on the antitumor activity of AAL and may be a helpful strategy for reducing the dosage of lectin used in antitumor therapy. The autophagy inhibitor may be a synergist of certain antitumor drugs that can induce both apoptosis and autophagy.